Exciting new treatment approaches for pathyphysiologic mechanisms of sickle cell disease.
During the past several decades, our understanding of the complex pathophysiology of vasoocclusion associated with sickle cell disease has improved greatly. Interaction of genes, hemoglobin molecules, red cell membrane and metabolic changes, cell-cell interactions and cell-plasma interactions, red cell adhesion to vascular endothelium, activation of coagulation, and vascular reactivity play a role in vasoocclusion. Penicillin prophylaxis of pneumococcal infections and appropriate use of blood transfusions and other supportive measures improved survival of sickle cell patients. Hydroxyurea made a major impact on sickle cell therapy when it was shown to decrease acute painful episodes, acute chest syndrome, and the need for blood transfusion in adults. Significant experience in the use of hydroxyurea has been accumulated in older children. The benefits and risks of hydroxyurea for younger children and long-term risks in all patients will be evaluated in future investigations. Other promising therapies include butyrate compounds, clotrimazole, magnesium supplementation, poloxamer 188, antiadhesion agents, anticoagulant approaches, and nitric oxide. Hemopoietic transplantation remains the only curative therapy. However, several transgenic mouse models are available for studies of gene therapy or other treatment approaches on biochemical, cellular, and pathologic effects of mutant genes.
Mankad
V N
VN
Department of Pediatrics, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000328:Adult; D000755:Anemia, Sickle Cell / Q000503:physiopathology / Q000628:therapy*; D000818:Animals; D002648:Child; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D015316:Genetic Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007511:Ischemia / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D007938:Leukemia / Q000139:chemically induced; D051379:Mice; D008822:Mice, Transgenic; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D013927:Thrombosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy
D006918:Hydroxyurea